Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity

Circulation

Volumn 97, Issue 4, 1998, Pages 350-355

  Valles, Juana ^a,b   Teresa Santos, M ^a   Aznar, Justo ^b   Osa, Ana ^b   Lago, Aida ^b   Cosin, Juan ^a   Sanchez, Elena ^b   Broekman, M Johan ^c   Marcus, Aaron J ^c  

^a Research Center   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Aspirin; Blood cells; Cardiovascular diseases; Cerebrovascular disorders; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYPNOTIC SEDATIVE AGENT; THROMBOXANE B2; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CELL INTERACTION; CEREBROVASCULAR DISEASE; DRUG EFFICACY; ERYTHROCYTE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOSIS PREVENTION;

EID: 0345131724     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.4.350     Document Type: Article

References (27)

1. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320-331.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized mais of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
3. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.
4. Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects. Chest 1995;108(suppl 4):S247-S257.
5. Marcus AJ. Platelets and their disorders. In: Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis. 3rd ed. Philadelphia, Pa: WB Saunders; 1996:79-137.
6. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Frozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System. 2nd ed. New York, NY: Raven Press; 1992:219-273.
7. Lopezfarre A, Caramelo C, Esteban A, Alberola ML, Millas I, Monton M, Casado S. Effects of ASA on platelet-neutrophil interactions: role of nitric oxide and endothelin-1. Circulation. 1995;91:2080-2088.
8. Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ. Islam N. Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest. 1991;87:571-580.
9. Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, Broekman MJ, Safier LB. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, ADP release, and recruitment. Blood. 1991;78:154-162.
10. Valles J, Santos MT, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Aznar J. Downregulation of human platelet reactivity by neutrophils: participation of lipoxygenase derivatives and adhesive proteins. J Clin Invest. 1993;92:1357-1365.
11. Santos MT, Valles J, Aznar J, Perez-Requejo JL. Role of red blood cells in the early stage of platelet activation by collagen. Thromb Haemost. 1986;56:376-381.
12. Perez-Requejo JL, Aznar J, Santos MT, Valles J. Early platelet-collagen interactions in whole blood and their modifications by ASA and dipyridamole evaluated by a new method (Basic Wave). Thromb Haemost. 1985;54:799-803.
13. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity: reduction by ASA. Circulation. 1997;95:63-68.
14. Rocca B, FitzGerald GA. Simply read: erythrocytes modulate platelet function. Should we rethink the way we give ASA? Circulation. 1997;95:11-13.
15. Marcus AJ. Eicosanoid interactions between platelets, endothelial cells and neutrophils. Methods Enzymol. 1990;187:585-399.
16. Hellem AJ. Borchgrevink CHRF. The role of red cells in haemostasis: the relation between haematocrit, bleeding time, and platelet adhesiveness. Br J Haematol. 1961;7:42-50.
17. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science. 1980;207:541-543.
18. Reimers RC, Sutera SP, Joist JH. Potentiation by red blood cells of shear-induced platelet aggregation: relative importance of chemical and physical mechanisms. Blood. 1984;64:1200-1206.
19. Saniabadi AR, Lowe GDO, Barbenel JC, Forbes CD. Haematocrit, bleeding time and platelet aggregation. Lancet. 1984;2:1409-1410.
20. Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low to high doses of ASA on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 1992;23:1400-1403.
21. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responder: a pilot study including 180 post-stroke patients. Thromb Res. 1993;71:397-403.
22. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ II, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of ASA in man. J Clin Invest. 1983;71:676-688.
23. Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ. Human gastric mucosal bleeding induced by low dose ASA, but not warfarin. BMJ. 1989;298:493-496.
24. Hawkey CJ, Somerville KW, Marshall S. Prophylaxis of ASA induced gastric mucosal bleeding with ranitidine. Aliment Pharmacol Ther. 1988;2:245-252.
25. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose ASA in healthy subjects. J Clin Invest. 1982;69:1366-1372.
26. Di Minno G, Silver MJ, Murphy S. Monitoring, the entry of new platelets into the circulation after ingestion of ASA. Blood. 1983;61:1081-1085.
27. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation. 1994;90:1908-1918.